Latest News

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Rachel Rubin, MD, for a conversation on advocacy, sexual medicine, and the evolving role of urologists in women’s health.

Rahul Winayak, MD, discusses the prognostic and predictive value of microbial dysbiosis in patients receiving CBM588 plus first-line immune checkpoint inhibitor-based regimens for metastatic renal cell carcinoma.

Eugene Pietzak, MD, highlights results from a phase 2 study of pembrolizumab plus BCG for patients with very high-risk, BCG-naive high-grade T1 NMIBC who declined upfront radical cystectomy.

Preston C. Sprenkle, MD, discusses the unmet needs, emerging solutions, and longer-term vision for MRI in prostate cancer care.

Unwanaobong Nseyo, MD, MHS, discusses a retrospective analysis comparing treatment continuation outcomes with minimally invasive therapies for idiopathic overactive bladder.

Sandip Prasad, MD, discusses 3-year data from the phase 3 ENVISION trial evaluating mitomycin for intravesical solution for recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

In this episode of The UroOnc Minute, Lourdes Guerrios-Rivera, MD, discusses strategies to improve patient engagement and adherence during active surveillance for prostate cancer, highlighting the critical roles of education, communication, and structured follow-up.

The agency is requesting a removal of the limitation of use for age-related hypogonadism as well as updated warnings related to prostate cancer risk and benign prostatic hyperplasia.

Data from the RAMPART trial showed that durvalumab monotherapy missed the DFS threshold in resected RCC, though the combination with tremelimumab showed significant benefit.

The prospective RELIEF study will evaluate the safety and preliminary efficacy of IRE delivered via the NanoKnife System for BPH-related symptoms.

In this episode of Pearls & Perspectives, Thomas F. Stringer, MD, FACS, discusses his journey from private practice to academic urology, his priorities as incoming AUA president, and opportunities to improve men's health engagement and education.

The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.

Daniel J. George, MD, discusses the clinical significance of the FDA approval of capivasertib, practical considerations for PTEN testing and toxicity management, and the broader implications of precision medicine for patients with advanced prostate cancer.